Objective The aim of the present study was to examine the association of serotonin -related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug.
Methods 230 patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4 weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), HTRA1 rs6295, HTR2A rs6313 and COMT rs4680 genes were genotyped and assessed for allele.
Results The allelic model showed that the SLC6A4 rs140701 variant was significantly associated with increased risk of PD(OR = 0.624, 95% CI 0.450-0.864, p <0.05), and significant results was found in the dominant model(OR = 0.546; 95% CI, 0.371-0.804, p <0.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR = 0.205, 95% CI 0.128-0.328; OR = 0.249, 95% CI 0.155-0.401, both p <0.001), and indicated the PD patients with S-allele had a poorer response to sertraline than L-allele carriers.
Conclusions The present study suggest that the SLC6A4 rs140701 variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertralines in the treatment of PD.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
On 20 Jul, 2020
On 20 Jul, 2020
On 16 Jul, 2020
Received 02 Jul, 2020
Received 17 Jun, 2020
On 13 Jun, 2020
On 12 Jun, 2020
Invitations sent on 09 Jun, 2020
On 08 Jun, 2020
On 07 Jun, 2020
On 07 Jun, 2020
Posted 10 Mar, 2020
On 18 May, 2020
Received 17 May, 2020
On 22 Apr, 2020
Received 13 Apr, 2020
Received 31 Mar, 2020
On 26 Mar, 2020
Invitations sent on 10 Mar, 2020
On 10 Mar, 2020
On 27 Feb, 2020
On 27 Feb, 2020
On 26 Feb, 2020
On 26 Feb, 2020
On 20 Jul, 2020
On 20 Jul, 2020
On 16 Jul, 2020
Received 02 Jul, 2020
Received 17 Jun, 2020
On 13 Jun, 2020
On 12 Jun, 2020
Invitations sent on 09 Jun, 2020
On 08 Jun, 2020
On 07 Jun, 2020
On 07 Jun, 2020
Posted 10 Mar, 2020
On 18 May, 2020
Received 17 May, 2020
On 22 Apr, 2020
Received 13 Apr, 2020
Received 31 Mar, 2020
On 26 Mar, 2020
Invitations sent on 10 Mar, 2020
On 10 Mar, 2020
On 27 Feb, 2020
On 27 Feb, 2020
On 26 Feb, 2020
On 26 Feb, 2020
Objective The aim of the present study was to examine the association of serotonin -related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug.
Methods 230 patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4 weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), HTRA1 rs6295, HTR2A rs6313 and COMT rs4680 genes were genotyped and assessed for allele.
Results The allelic model showed that the SLC6A4 rs140701 variant was significantly associated with increased risk of PD(OR = 0.624, 95% CI 0.450-0.864, p <0.05), and significant results was found in the dominant model(OR = 0.546; 95% CI, 0.371-0.804, p <0.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR = 0.205, 95% CI 0.128-0.328; OR = 0.249, 95% CI 0.155-0.401, both p <0.001), and indicated the PD patients with S-allele had a poorer response to sertraline than L-allele carriers.
Conclusions The present study suggest that the SLC6A4 rs140701 variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertralines in the treatment of PD.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...